EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies

Jean-Jacques Kiladjian iD, Bruno Cassinat iD

American Journal of Hematology · 2023-05 · 98 (5) · 794-800

DOI: 10.1002/ajh.26896 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 15.03.2023. Verfasst von Jean-Jacques Kiladjian und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre d'Investigations Cliniques, Université Paris Cité, AP-HP, Hôpital Saint-Louis, Paris, France. Hauptthemen laut MEDLINE: Venous Thrombosis, Budd-Chiari Syndrome, Myeloproliferative Disorders, Bone Marrow Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloproliferative neoplasms (MPNs) are the most common etiologies of primary splanchnic vein thrombosis, present in almost forty percent of patients with Budd‐Chiari syndrome or portal vein thrombosis. Diagnosis of MPNs can be difficult in these patients because key characteristics, such as elevated blood cell counts and splenomegaly, are confounded by portal hypertension or bleeding complications. In recent years, diagnostic tools have improved to provide more accurate diagnosis and classification of MPNs. Although bone marrow biopsy findings remain a major diagnostic criterion, molecular markers are playing an increasing role not only in diagnosis but also in better estimating prognosis. Therefore, though screening for JAK2V617F mutation should be the starting point of the diagnostic workup performed in all patients with splanchnic vein thrombosis, a multidisciplinary approach is needed to accurately diagnose the subtype of myeloproliferative neoplasm, recommend the useful additional tests (bone marrow biopsy, search for an additional mutation using targeted next‐generation sequencing), and suggest the best treatment strategy. Indeed, providing a specific expert care pathway for patients with splanchnic vein thrombosis and underlying myeloproliferative neoplasm is crucial to determine the optimal management to reduce the risk of both hematological and hepatic complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThrombosisBudd-Chiari SyndromeMyeloproliferative DisordersBone Marrow NeoplasmsHumansPortal VeinSplanchnic CirculationJanus Kinase 2

Substanzen

Janus Kinase 2

Autor:innen und Institutionen

  • Centre d'Investigations Cliniques, Université Paris Cité, AP-HP, Hôpital Saint-Louis, Paris, France.
  • INSERM UMR 1131, Institut de Recherche Saint-Louis, Paris, France.
  • Laboratoire de Biologie Cellulaire, AP-HP, Hôpital Saint-Louis, Paris, France.

ORCID-Profile: Jean-Jacques Kiladjian, Bruno Cassinat

Zitieren

APA

Kiladjian, J. J., & Cassinat, B. (2023). Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies. American Journal of Hematology, 98(5), 794-800. https://doi.org/10.1002/ajh.26896

Vancouver

Kiladjian JJ, Cassinat B. Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies. American Journal of Hematology. 2023;98(5):794-800. doi:10.1002/ajh.26896

BibTeX
@article{Kiladjian2023,
  author = {Kiladjian, Jean-Jacques and Cassinat, Bruno},
  title = {Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies},
  journal = {American Journal of Hematology},
  year = {2023},
  volume = {98},
  number = {5},
  pages = {794--800},
  doi = {10.1002/ajh.26896}
}
Kostenlos starten →